COVID-19 Sample Collection and Vaccine Studies

Document text

Principal Investigator: Julie E. Ledgerwood
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2020
Award: $592,800
Funding agency: National Institute of Allergy and Infectious Diseases

The evaluation of a vaccine candidate targeting COVID-19 and collection of samples to support translational immunology research support the broader VRC mission.  For this project, sample collection was conducted under the VRC 200 protocol while the evaluation of an investigational vaccine candidate was conducted under the DMID 20-003 protocol. 

VRC 200: A Multicenter Specimen Collection Protocol to Obtain Human Biological Samples for Research Studies

DMID 20-0003: Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults

Terms: <2019 novel coronavirus><2019-nCoV><21+ years old><Adult><Adult Human><Assay><Bioassay><Biologic Assays><Biological><Biological Assay><COVID-19><COVID19><Cellular Immune Function><Development><Dose><Evaluation><Human><Immune response><Immunity><Immunological response><Immunology><Individual><Infection><Investigation><Measures><Messenger RNA><Mission><Modern Man><Phase><Preventive><Protocol><Protocols documentation><Research><Research Support><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Safety><Sampling><Severe acute respiratory syndrome coronavirus 2><Severity of illness><Therapeutic><Vaccines><Wuhan coronavirus><adulthood><corona virus disease 2019><coronavirus disease 2019><developmental><disease severity><host response><immune function><immunogenicity><immunoresponse><mRNA><open label><open label study><research study><safety study><sample collection><specimen collection><vaccination study><vaccination trial><vaccine candidate><vaccine study><vaccine trial>